Short Interest in MDxHealth SA (NASDAQ:MDXH) Declines By 22.7%

MDxHealth SA (NASDAQ:MDXH) was the target of a large drop in short interest in February. As of February 15th, there was short interest totalling 13,300 shares, a drop of 22.7% from the January 31st total of 17,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 121,000 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. OneDigital Investment Advisors LLC grew its position in MDxHealth by 15.3% during the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock valued at $120,000 after buying an additional 7,656 shares during the period. FAS Wealth Partners Inc. boosted its holdings in MDxHealth by 49.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock worth $58,000 after buying an additional 8,100 shares during the period. Oppenheimer & Co. Inc. grew its stake in MDxHealth by 100.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock valued at $47,000 after buying an additional 10,000 shares in the last quarter. Geode Capital Management LLC purchased a new position in MDxHealth in the 4th quarter valued at approximately $25,000. Finally, XTX Topco Ltd bought a new stake in MDxHealth during the 4th quarter valued at $63,000.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler lowered their price objective on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th.

MDxHealth Stock Up 3.8 %

MDxHealth stock traded up $0.06 during midday trading on Thursday, hitting $1.62. 64,139 shares of the stock were exchanged, compared to its average volume of 86,040. MDxHealth has a 52-week low of $1.55 and a 52-week high of $3.85. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The business’s 50-day moving average price is $1.98 and its 200-day moving average price is $2.17. The stock has a market capitalization of $76.56 million, a price-to-earnings ratio of -1.04 and a beta of 1.34.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.07. The firm had revenue of $24.74 million for the quarter, compared to analysts’ expectations of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. On average, research analysts expect that MDxHealth will post -1.15 EPS for the current fiscal year.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.